{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:52:45Z","timestamp":1790639565599,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008659","name":"ECTRIMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010443","name":"RACP Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030827","name":"NHS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The relapse risk following discontinuation of immunomodulatory treatment in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unknown. Evidence suggests that \u2018at least\u2019 3 months of oral corticosteroids reduces relapse risk after a single attack, and that it may be possible to stop maintenance treatment in relapsing stable disease, but the optimal duration of treatment has yet to be defined. We therefore investigated relapse outcomes following discontinuation of maintenance treatment.<\/jats:p>\n                  <jats:p>We conducted a cohort study of MOGAD patients seen in the Oxford Neuromyelitis Optica Highly Specialised Service between January 2010 and May 2025. Patients with MOGAD who had at least 12 months of follow-up and who commenced and then discontinued maintenance treatment were included. Associations of factors including treatment duration before discontinuation, disease course at discontinuation (after a single attack\/monophasic or relapsing course) and MOG IgG1 status on live cell-based assay were investigated. The primary outcome was time-to-relapse following treatment discontinuation. Cox regression was used.<\/jats:p>\n                  <jats:p>We included 190 MOGAD patients with 236 discontinued treatment intervals. There were 150 (63.6%) discontinuations after a single attack and before a first relapse in patients with monophasic disease, and 86 (36.4%) discontinuations in patients with relapsing disease. Most patients used corticosteroids alone [84.7% of immunomodulatory treatment (IT) intervals], and non-steroid ITs were used in 15.2% of IT intervals, either alone or in combination with steroids. Post-discontinuation relapse occurred after 92 (39.0%) discontinuations, at a median time of 5.4 (interquartile range 1.4\u201320.1) months after treatment cessation. Those who relapsed were more likely to have a relapsing course at the time of discontinuation (50% versus 27.8%, P = 0.001) and a positive\/low-positive pre-discontinuation MOG IgG1 result (89.8% versus 71.5%, P = 0.005). In a multivariable analysis, a relapsing course at the time of discontinuation was associated with an elevated relapse risk (hazard ratio 1.95, 95% confidence interval 1.25\u20133.06, P = 0.003). Overall, prolonged treatment beyond 3 months before discontinuation significantly reduced relapse risk. Optimal treatment durations were estimated to be 10\u201318 months for patients treated after their first attack and 20\u201330 months for relapsing patients, after which treatment discontinuation could be considered in patients who were relapse-free on treatment.<\/jats:p>\n                  <jats:p>Identifying the relapse risk when discontinuing maintenance immunomodulatory treatment in MOGAD should aid management decisions in patients presenting with their first attack and also in those on longer-term treatment for relapsing disease. Our findings, from a cohort predominantly treated with steroids, provide evidence to inform joint decision-making for stable patients who are considering treatment cessation.<\/jats:p>","DOI":"10.1093\/brain\/awag006","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:55:45Z","timestamp":1767963345000},"page":"3242-3253","source":"Crossref","is-referenced-by-count":10,"title":["Optimal strategies for treatment discontinuation in MOG antibody-associated disease"],"prefix":"10.1093","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-6612","authenticated-orcid":false,"given":"Wei Z","family":"Yeh","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Neuroscience, School of Translational Medicine, Monash University , Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Department of Neurology, Alfred Health , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Francis","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cooper","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex National Health Service Foundation Trust Department of Neurology, , Brighton BN2 5BE ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqar","family":"Rashid","sequence":"additional","affiliation":[{"name":"St George\u2019s University Hospitals National Health Service Foundation Trust Department of Neurology, , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roswell","family":"Martin","sequence":"additional","affiliation":[{"name":"Gloucestershire Hospitals National Health Service Foundation Trust Department of Neurology, , Gloucestershire GL1 3NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hobart","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth National Health Service Foundation Trust Department of Neurology, , Plymouth PL6 5FP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Halfpenny","sequence":"additional","affiliation":[{"name":"University Hospitals Southampton National Health Service Foundation Trust Department of Neurology, , Southampton SO16 6YD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Williams","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust Department of Neurology, , London SE1 7EH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Eye Department, King\u2019s College Hospital , London SE5 9RS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology, Great Ormond Street Hospital for Children , London WC1N 3BH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-9657","authenticated-orcid":false,"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology, Great Ormond Street Hospital for Children , London WC1N 3BH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[{"name":"Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University London , London EC1M 6BQ ,","place":["UK"]},{"name":"Royal London Hospital, Barts Health National Health Service Foundation Trust , London E1 1BB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, Oxford Autoimmune Neurology Diagnostic Laboratory, University of Oxford , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilakshmi M","family":"Sharma","sequence":"additional","affiliation":[{"name":"Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]},{"name":"Kennedy Institute for Rheumatology, University of Oxford , Oxford OX3 7FY ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, School of Translational Medicine, Monash University , Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Department of Neurology, Alfred Health , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Geraldes","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-2190","authenticated-orcid":false,"given":"Sithara","family":"Ramdas","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Leite","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX3 9DU ,","place":["UK"]},{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026090711262512600_awag006-B1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"2026090711262512600_awag006-B2","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: A UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2026090711262512600_awag006-B3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090711262512600_awag006-B4","doi-asserted-by":"crossref","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody\u2013associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2026090711262512600_awag006-B5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol."},{"key":"2026090711262512600_awag006-B6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"2026090711262512600_awag006-B7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2026090711262512600_awag006-B8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"2026090711262512600_awag006-B9","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-021-10914-x","article-title":"Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"269","author":"Akaishi","year":"2022","journal-title":"J Neurol"},{"key":"2026090711262512600_awag006-B10","doi-asserted-by":"crossref","first-page":"e200309","DOI":"10.1212\/NXI.0000000000200309","article-title":"A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack","volume":"11","author":"Xu","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026090711262512600_awag006-B11","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026090711262512600_awag006-B12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol."},{"key":"2026090711262512600_awag006-B13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: A multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090711262512600_awag006-B14","doi-asserted-by":"crossref","first-page":"e200035","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026090711262512600_awag006-B15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti\u2013myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026090711262512600_awag006-B16","author":"Therneau"},{"key":"2026090711262512600_awag006-B17","author":"R Core Team"},{"key":"2026090711262512600_awag006-B18","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw."},{"key":"2026090711262512600_awag006-B19","first-page":"1","article-title":"Mice: Multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw."},{"key":"2026090711262512600_awag006-B20","author":"Harrell"},{"key":"2026090711262512600_awag006-B21","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"2026090711262512600_awag006-B22","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: Results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol"},{"key":"2026090711262512600_awag006-B23","doi-asserted-by":"crossref","first-page":"e200065","DOI":"10.1212\/NXI.0000000000200065","article-title":"Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD","volume":"10","author":"Nosadini","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026090711262512600_awag006-B24","doi-asserted-by":"crossref","first-page":"e209624","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: The MOGADOR2 study","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"key":"2026090711262512600_awag006-B25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1177\/13524585251320046","article-title":"Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"31","author":"Kang","year":"2025","journal-title":"Mult Scler"},{"key":"2026090711262512600_awag006-B26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?","volume":"94","author":"Chen","year":"2023","journal-title":"Ann Neurol"},{"key":"2026090711262512600_awag006-B27","doi-asserted-by":"crossref","first-page":"104760","DOI":"10.1016\/j.msard.2023.104760","article-title":"A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD)","volume":"75","author":"Leite","year":"2023","journal-title":"Mult Scler Relat Disord."},{"key":"2026090711262512600_awag006-B28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026090711262512600_awag006-B29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090711262512600_awag006-B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: An international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am J Ophthalmol."},{"key":"2026090711262512600_awag006-B31","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026090711262512600_awag006-B32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12883-022-02612-6","article-title":"Failure of alemtuzumab therapy in three patients with MOG antibody associated disease","volume":"22","author":"Seneviratne","year":"2022","journal-title":"BMC Neurol."},{"key":"2026090711262512600_awag006-B33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1212\/WNL.0000000000004087","article-title":"Failure of alemtuzumab therapy to control MOG encephalomyelitis","volume":"89","author":"Wildemann","year":"2017","journal-title":"Neurology"},{"key":"2026090711262512600_awag006-B34","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"2026090711262512600_awag006-B35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2026090711262512600_awag006-B36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"2026090711262512600_awag006-B37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awag006\/66752824\/awag006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/9\/3242\/66752824\/awag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/9\/3242\/66752824\/awag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:26:36Z","timestamp":1788794796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/9\/3242\/8460602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awag006","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,2,4]]}}}